The interplay between the cutaneous nervous and immune systems plays a notable role in the pathogenesis of chronic itch, a debilitating symptom associated with conditions such as atopic dermatitis, psoriasis, and prurigo nodularis. Recent advances in neuro-immune biology have discovered the importance of transient receptor potential (TRP) channels, particularly TRPV1, TRPA1, and TRPV4, as critical mediators in the transmission and modulation of pruritic signals. These ion channels, expressed on sensory neurons and keratinocytes, serve as molecular conduits linking environmental, immunological, and neuronal stimuli to itch perception. Dysregulated TRP channel activity has been implicated in the amplification of chronic itch through mechanisms such as mast cell degranulation, the release of pro-inflammatory cytokines, and sensory nerve hypersensitization. Emerging therapies targeting these channels offer a novel approach to interrupting this pathological crosstalk. TRPV1 and TRPA1 antagonists have demonstrated efficacy in preclinical and early clinical studies by attenuating neuronal excitation and inflammatory cascades, while TRPV4 modulators hold promise in mitigating itch associated with mechanical and thermal stimuli. Additionally, the downstream signaling pathways of TRP channels, including the release of calcitonin gene-related peptide (CGRP) and substance P, present further therapeutic targets for modulating neurogenic inflammation and sensory input. Beyond pharmacologic interventions, insights into neuro-immune interactions have guided the development of biologics that dampen cytokine-driven pruritus, including IL-31 and IL-4/IL-13 inhibitors. The exploration of cutaneous neuro-immune interactions and TRP channel biology has unveiled transformative opportunities for understanding and treating chronic itch, highlighting a promising avenue for addressing the unmet needs of patients suffering from this distressing condition.
Matterne, U., Apfelbacher, C., Loerbroks, A., Schwarzer, T., Büttner, M., Ofenloch, R., et al. (2011) Prevalence, Correlates and Characteristics of Chronic Pruritus: A Population-Based Cross-Sectional Study. ActaDermatoVenereologica, 91, 674-679. https://doi.org/10.2340/00015555-1159
[3]
Abuabara, K., Magyari, A., McCulloch, C.E., Linos, E., Margolis, D.J. and Langan, S.M. (2019) Prevalence of Atopic Eczema among Patients Seen in Primary Care: Data from the Health Improvement Network. AnnalsofInternalMedicine, 170, 354-356. https://doi.org/10.7326/m18-2246
[4]
Armstrong, A.W., Mehta, M.D., Schupp, C.W., Gondo, G.C., Bell, S.J. and Griffiths, C.E.M. (2021) Psoriasis Prevalence in Adults in the United States. JAMADermatology, 157, 940-946. https://doi.org/10.1001/jamadermatol.2021.2007
[5]
Ständer, S., Ketz, M., Kossack, N., Akumo, D., Pignot, M., Gabriel, S., et al. (2020) Epidemiology of Prurigo Nodularis Compared with Psoriasis in Germany: A Claims Database Analysis. ActaDermatoVenereologica, 100, adv00309. https://doi.org/10.2340/00015555-3655
[6]
Roh, Y.S., Choi, J., Sutaria, N. and Kwatra, S.G. (2022) Itch: Epidemiology, Clinical Presentation, and Diagnostic Workup. JournaloftheAmericanAcademyofDermatology, 86, 1-14. https://doi.org/10.1016/j.jaad.2021.07.076
[7]
Chisolm S.S. (2023) A Review of the Current Management and burden of Prurigo Nodularis in the United States. The American Journal of Managed Care, 29, S63-S72. https://doi.org/10.37765/ajmc.2023.89366
[8]
Feng, J., Yang, P., Mack, M.R., Dryn, D., Luo, J., Gong, X., et al. (2017) Sensory TRP Channels Contribute Differentially to Skin Inflammation and Persistent Itch. NatureCommunications, 8, Article No. 980. https://doi.org/10.1038/s41467-017-01056-8
[9]
Gouin, O., L’Herondelle, K., Lebonvallet, N., Le Gall-Ianotto, C., Sakka, M., Buhé, V., et al. (2017) TRPV1 and TRPA1 in Cutaneous Neurogenic and Chronic Inflammation: Pro-Inflammatory Response Induced by Their Activation and Their Sensitization. Protein&Cell, 8, 644-661. https://doi.org/10.1007/s13238-017-0395-5
[10]
Zhang, Q., Henry, G. and Chen, Y. (2021) Emerging Role of Transient Receptor Potential Vanilloid 4 (TRPV4) Ion Channel in Acute and Chronic Itch. InternationalJournalofMolecularSciences, 22, Article 7591. https://doi.org/10.3390/ijms22147591
[11]
Fernández-Carvajal, A., Fernández-Ballester, G. and Ferrer-Montiel, A. (2022) TRPV1 in Chronic Pruritus and Pain: Soft Modulation as a Therapeutic Strategy. FrontiersinMolecularNeuroscience, 15, Article 930964. https://doi.org/10.3389/fnmol.2022.930964
[12]
Cevikbas, F. and Lerner, E.A. (2020) Physiology and Pathophysiology of Itch. PhysiologicalReviews, 100, 945-982. https://doi.org/10.1152/physrev.00017.2019
[13]
Fan, J. and Mishra, S.K. (2021) The Emerging Role of Neuroimmune Interactions in Atopic Dermatitis and Itch. TheFEBSJournal, 289, 2723-2735. https://doi.org/10.1111/febs.15860
[14]
Tominaga, M. and Takamori, K. (2022) Peripheral Itch Sensitization in Atopic Dermatitis. AllergologyInternational, 71, 265-277. https://doi.org/10.1016/j.alit.2022.04.003
[15]
Steinhoff, M., Ahmad, F., Pandey, A., Datsi, A., AlHammadi, A., Al-Khawaga, S., et al. (2022) Neuroimmune communication regulating pruritus in atopic dermatitis. JournalofAllergyandClinicalImmunology, 149, 1875-1898. https://doi.org/10.1016/j.jaci.2022.03.010
[16]
Sun, S. and Dong, X. (2015) TRP Channels and Itch. SeminarsinImmunopathology, 38, 293-307. https://doi.org/10.1007/s00281-015-0530-4
[17]
Gupta, K. and Harvima, I.T. (2018) Mast Cell-Neural Interactions Contribute to Pain and Itch. ImmunologicalReviews, 282, 168-187. https://doi.org/10.1111/imr.12622
[18]
Dong, X. and Dong, X. (2018) Peripheral and Central Mechanisms of Itch. Neuron, 98, 482-494. https://doi.org/10.1016/j.neuron.2018.03.023
[19]
Mahmoud, O., Soares, G.B. and Yosipovitch, G. (2022) Transient Receptor Potential Channels and Itch. InternationalJournalofMolecularSciences, 24, Article 420. https://doi.org/10.3390/ijms24010420
[20]
Koivisto, A. and Szallasi, A. (2023) Targeting TRP Channels for Pain, Itch and Neurogenic Inflammation. InternationalJournalofMolecularSciences, 25, Article 320. https://doi.org/10.3390/ijms25010320
[21]
Shim, W., Tak, M., Lee, M., Kim, M., Kim, M., Koo, J., et al. (2007) TRPV1 Mediates Histamine-Induced Itching via the Activation of Phospholipase A2 and 12-Lipoxygenase. TheJournalofNeuroscience, 27, 2331-2337. https://doi.org/10.1523/jneurosci.4643-06.2007
[22]
Gouin, O., L'Herondelle, K., Buscaglia, P., Le Gall-Ianotto, C., Philippe, R., Legoux, N., et al. (2018) Major Role for TRPV1 and InsP3R in PAR2-Elicited Inflammatory Mediator Production in Differentiated Human Keratinocytes. JournalofInvestigativeDermatology, 138, 1564-1572. https://doi.org/10.1016/j.jid.2018.01.034
[23]
Xu, R., Ma, L., Chen, T., Zhang, W., Chang, K. and Wang, J. (2023) Sophorolipid Inhibits Histamine-Induced Itch by Decreasing PLC/IP3R Signaling Pathway Activation and Modulating TRPV1 Activity. ScientificReports, 13, Article No. 7957. https://doi.org/10.1038/s41598-023-35158-9
[24]
Moore, C., Gupta, R., Jordt, S., Chen, Y. and Liedtke, W.B. (2017) Regulation of Pain and Itch by TRP Channels. NeuroscienceBulletin, 34, 120-142. https://doi.org/10.1007/s12264-017-0200-8
[25]
Dai, Y., Wang, S., Tominaga, M., Yamamoto, S., Fukuoka, T., Higashi, T., et al. (2007) Sensitization of TRPA1 by PAR2 Contributes to the Sensation of Inflammatory Pain. JournalofClinicalInvestigation, 117, 1979-1987. https://doi.org/10.1172/jci30951
[26]
Akiyama, T., Ivanov, M., Nagamine, M., Davoodi, A., Carstens, M.I., Ikoma, A., et al. (2016) Involvement of TRPV4 in Serotonin-Evoked Scratching. JournalofInvestigativeDermatology, 136, 154-160. https://doi.org/10.1038/jid.2015.388
[27]
Chen, Y., Fang, Q., Wang, Z., Zhang, J.Y., MacLeod, A.S., Hall, R.P., et al. (2016) Transient Receptor Potential Vanilloid 4 Ion Channel Functions as a Pruriceptor in Epidermal Keratinocytes to Evoke Histaminergic Itch. JournalofBiologicalChemistry, 291, 10252-10262. https://doi.org/10.1074/jbc.m116.716464
[28]
Macphee, C.H., Dong, X., Peng, Q., Paone, D.V., Skov, P.S., Baumann, K., et al. (2024) Pharmacological Blockade of the Mast Cell MRGPRX2 Receptor Supports Investigation of Its Relevance in Skin Disorders. FrontiersinImmunology, 15, Article 1433982. https://doi.org/10.3389/fimmu.2024.1433982
[29]
Kwiatkowska, D. and Reich, A. (2021) Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis. ActaDermato-Venereologica, 101, adv00583. https://doi.org/10.2340/actadv.v101.350
[30]
Voisin, T. and Chiu, I.M. (2019) Mast Cells Get on Your Nerves in Itch. Immunity, 50, 1117-1119. https://doi.org/10.1016/j.immuni.2019.04.007
[31]
Bağci, I.S. and Ruzicka, T. (2018) IL-31: A New Key Player in Dermatology and Beyond. JournalofAllergyandClinicalImmunology, 141, 858-866. https://doi.org/10.1016/j.jaci.2017.10.045
[32]
Kim, S., Jun, C., Suk, K., Choi, B., Lim, H., Park, S., et al. (2005) Gallic Acid Inhibits Histamine Release and Pro-Inflammatory Cytokine Production in Mast Cells. ToxicologicalSciences, 91, 123-131. https://doi.org/10.1093/toxsci/kfj063
[33]
Zheng, Y., Huang, Q., Zhang, Y., Geng, L., Wang, W., Zhang, H., et al. (2023) Multimodal Roles of Transient Receptor Potential Channel Activation in Inducing Pathological Tissue Scarification. FrontiersinImmunology, 14, Article 1237992. https://doi.org/10.3389/fimmu.2023.1237992
[34]
Wang, F., Yang, T.B. and Kim, B.S. (2020) The Return of the Mast Cell: New Roles in Neuroimmune Itch Biology. JournalofInvestigativeDermatology, 140, 945-951. https://doi.org/10.1016/j.jid.2019.12.011
[35]
Mahmoud, O., Oladipo, O., Mahmoud, R.H. and Yosipovitch, G. (2023) Itch: From the Skin to the Brain—Peripheral and Central Neural Sensitization in Chronic Itch. FrontiersinMolecularNeuroscience, 16, Article 1272230. https://doi.org/10.3389/fnmol.2023.1272230
[36]
Gavva, N.R., Treanor, J.J.S., Garami, A., Fang, L., Surapaneni, S., Akrami, A., et al. (2008) Pharmacological Blockade of the Vanilloid Receptor TRPV1 Elicits Marked Hyperthermia in Humans. Pain, 136, 202-210. https://doi.org/10.1016/j.pain.2008.01.024
[37]
Go, E.J., Lee, J.Y., Kim, Y.H. and Park, C. (2024) Site-Specific Transient Receptor Potential Channel Mechanisms and Their Characteristics for Targeted Chronic Itch Treatment. Biomolecules, 14, Article 107. https://doi.org/10.3390/biom14010107
[38]
Avila, C., Massick, S., Kaffenberger, B.H., Kwatra, S.G. and Bechtel, M. (2020) Cannabinoids for the Treatment of Chronic Pruritus: A Review. JournaloftheAmericanAcademyofDermatology, 82, 1205-1212. https://doi.org/10.1016/j.jaad.2020.01.036
[39]
Park, C.W., Kim, B.J., Lee, Y.W., Won, C., Park, C.O., Chung, B.Y., et al. (2022) Asivatrep, a TRPV1 Antagonist, for the Topical Treatment of Atopic Dermatitis: Phase 3, Randomized, Vehicle-Controlled Study (CAPTAIN-AD). JournalofAllergyandClinicalImmunology, 149, 1340-1347.e4. https://doi.org/10.1016/j.jaci.2021.09.024
[40]
Mahmoud, R.H., Brooks, S.G. and Yosipovitch, G. (2024) Current and Emerging Drugs for the Treatment of Pruritus: An Update of the Literature. ExpertOpiniononPharmacotherapy, 25, 655-672. https://doi.org/10.1080/14656566.2024.2349193
[41]
Gibson, R.A., Robertson, J., Mistry, H., McCallum, S., Fernando, D., Wyres, M., et al. (2014) A Randomised Trial Evaluating the Effects of the TRPV1 Antagonist SB705498 on Pruritus Induced by Histamine, and Cowhage Challenge in Healthy Volunteers. PLOSONE, 9, e100610. https://doi.org/10.1371/journal.pone.0100610
[42]
Sun, M., Chen, Z., Ding, H. and Feng, J. (2024) Molecular and Cellular Mechanisms of Itch Sensation and the Anti-Itch Drug Targets. ActaPharmacologicaSinica, 46, 539-553. https://doi.org/10.1038/s41401-024-01400-x
[43]
Nattkemper, L.A., Zhi, K., Romero, K.E., Shah, S.M., Ju, T., Fourzali, K., et al. (2022) Antipruritic Effect of Topical Acetaminophen Gel in Histaminergic and Non-Histaminergic Itch Provocation: A Double-Blind, Vehicle-Controlled Pilot Study. ActaDermato-Venereologica, 102, adv00640. https://doi.org/10.2340/00015555-3910
[44]
Bartley, B., Pierce, C., Hivnor, C. and Valdes-Rodriguez, R. (2025) Topical Medications for Chronic Itch in Older Patients: Navigating a Pressing Need. Drugs&Aging, 42, 213-233. https://doi.org/10.1007/s40266-024-01174-1
[45]
Esancy, K. and Dhaka, A. (2024) Turning down the Body Heat: A Novel Mechanism for TRPV1 Antagonist-Induced Hyperthermia. Neuron, 112, 1727-1729. https://doi.org/10.1016/j.neuron.2024.04.031
[46]
Huang, Y., Ma, J., Bian, Y., Bai, Q., Gao, Y., Di, S., et al. (2024) TRPV1 Analgesics Disturb Core Body Temperature via a Biased Allosteric Mechanism Involving Conformations Distinct from That for Nociception. Neuron, 112, 1815-1831.e4. https://doi.org/10.1016/j.neuron.2024.02.016
[47]
Tsagareli, M.G., Follansbee, T., Iodi Carstens, M. and Carstens, E. (2023) Targeting Transient Receptor Potential (TRP) Channels, Mas-Related G-Protein-Coupled Receptors (Mrgprs), and Protease-Activated Receptors (PARs) to Relieve Itch. Pharmaceuticals, 16, Article 1707. https://doi.org/10.3390/ph16121707
[48]
Oh, M., Oh, S.Y., Lu, J., Lou, H., Myers, A.C., Zhu, Z., et al. (2013) TRPA1-Dependent Pruritus in IL-13-Induced Chronic Atopic Dermatitis. TheJournalofImmunology, 191, 5371-5382. https://doi.org/10.4049/jimmunol.1300300
[49]
Wong, L.S., Otsuka, A., Yamamoto, Y., Nonomura, Y., Nakashima, C., Kitayama, N., et al. (2018) TRPA1 Channel Participates in Tacrolimus-Induced Pruritus in a Chronic Contact Hypersensitivity Murine Model. JournalofDermatologicalScience, 89, 207-209. https://doi.org/10.1016/j.jdermsci.2017.10.012
[50]
Hoang, D., Wong, A. and Olympia, R.P. (2023) Looking Back to Move Forward: The Current State of Research on the Clinical Applications of Camphor-and Menthol-Containing Agents. Cureus, 15, e41426. https://doi.org/10.7759/cureus.41426
[51]
Kittaka, H., Yamanoi, Y. and Tominaga, M. (2017) Transient Receptor Potential Vanilloid 4 (TRPV4) Channel as a Target of Crotamiton and Its Bimodal Effects. PflügersArchiv—EuropeanJournalofPhysiology, 469, 1313-1323. https://doi.org/10.1007/s00424-017-1998-7
[52]
Qin, Z., Xiang, L., Zheng, S., Zhao, Y., Qin, Y., Zhang, L., et al. (2023) Vitexin Inhibits Pain and Itch Behavior via Modulating TRPV4 Activity in Mice. Biomedicine&Pharmacotherapy, 165, Article ID: 115101. https://doi.org/10.1016/j.biopha.2023.115101
[53]
Yan, J., Ye, F., Ju, Y., Wang, D., Chen, J., Zhang, X., et al. (2021) Cimifugin Relieves Pruritus in Psoriasis by Inhibiting Trpv4. CellCalcium, 97, Article ID: 102429. https://doi.org/10.1016/j.ceca.2021.102429
[54]
Holzer, P. (1998) Neurogenic Vasodilatation and Plasma Leakage in the Skin. GeneralPharmacology: TheVascularSystem, 30, 5-11. https://doi.org/10.1016/s0306-3623(97)00078-5
[55]
Obreja, O., Rukwied, R., Steinhoff, M. and Schmelz, M. (2005) Neurogenic Components of Trypsin-and Thrombin-Induced Inflammation in Rat Skin, in Vivo. ExperimentalDermatology, 15, 58-65. https://doi.org/10.1111/j.0906-6705.2005.00392.x
[56]
Shimada, S.G., Shimada, K.A. and Collins, J.G. (2006) Scratching Behavior in Mice Induced by the Proteinase-Activated Receptor-2 Agonist, SLIGRL-NH2. EuropeanJournalofPharmacology, 530, 281-283. https://doi.org/10.1016/j.ejphar.2005.11.012
[57]
Costa, R., Marotta, D.M., Manjavachi, M.N., Fernandes, E.S., Lima-Garcia, J.F., Paszcuk, A.F., et al. (2008) Evidence for the Role of Neurogenic Inflammation Components in Trypsin-Elicited Scratching Behaviour in Mice. BritishJournalofPharmacology, 154, 1094-1103. https://doi.org/10.1038/bjp.2008.172
[58]
Amadesi, S., Cottrell, G.S., Divino, L., Chapman, K., Grady, E.F., Bautista, F., et al. (2006) Protease-Activated Receptor 2 Sensitizes TRPV1 by Protein Kinase Cɛ-and A-Dependent Mechanisms in Rats and Mice. TheJournalofPhysiology, 575, 555-571. https://doi.org/10.1113/jphysiol.2006.111534
[59]
Rogoz, K., Andersen, H.H., Lagerström, M.C. and Kullander, K. (2014) Multimodal Use of Calcitonin Gene-Related Peptide and Substance P in Itch and Acute Pain Uncovered by the Elimination of Vesicular Glutamate Transporter 2 from Transient Receptor Potential Cation Channel Subfamily V Member 1 Neurons. TheJournalofNeuroscience, 34, 14055-14068. https://doi.org/10.1523/jneurosci.1722-14.2014
[60]
Akiyama, T., Tominaga, M., Takamori, K., Carstens, M.I. and Carstens, E. (2014) Roles of Glutamate, Substance P, and Gastrin-Releasing Peptide as Spinal Neurotransmitters of Histaminergic and Nonhistaminergic Itch. Pain, 155, 80-92. https://doi.org/10.1016/j.pain.2013.09.011
[61]
Silverberg, J.I., Wollenberg, A., Reich, A., Thaçi, D., Legat, F.J., Papp, K.A., et al. (2024) Nemolizumab with Concomitant Topical Therapy in Adolescents and Adults with Moderate-To-Severe Atopic Dermatitis (ARCADIA 1 and ARCADIA 2): Results from Two Replicate, Double-Blind, Randomised Controlled Phase 3 Trials. TheLancet, 404, 445-460. https://doi.org/10.1016/s0140-6736(24)01203-0
[62]
Silverberg, J.I., Guttman-Yassky, E., Thaçi, D., Irvine, A.D., Stein Gold, L., Blauvelt, A., et al. (2023) Two Phase 3 Trials of Lebrikizumab for Moderate-To-Severe Atopic Dermatitis. NewEnglandJournalofMedicine, 388, 1080-1091. https://doi.org/10.1056/nejmoa2206714
[63]
Davis, D.M.R., Frazer-Green, L., Alikhan, A., Bercovitch, L., Cohen, D.E., Darr, J.M., et al. (2025) Focused Update: Guidelines of Care for the Management of Atopic Dermatitis in Adults. JournaloftheAmericanAcademyofDermatology, 93, 745.e1-745.e7. https://doi.org/10.1016/j.jaad.2025.05.1386
[64]
Sutaria, N., Adawi, W., Goldberg, R., Roh, Y.S., Choi, J. and Kwatra, S.G. (2022) Itch: Pathogenesis and Treatment. JournaloftheAmericanAcademyofDermatology, 86, 17-34. https://doi.org/10.1016/j.jaad.2021.07.078
[65]
Guo, C.J., Grabinski, N.S. and Liu, Q. (2022) Peripheral Mechanisms of Itch. JournalofInvestigativeDermatology, 142, 31-41. https://doi.org/10.1016/j.jid.2021.10.024
[66]
Mießner, H., Seidel, J. and Smith, E.S.J. (2022) In Vitro Models for Investigating Itch. FrontiersinMolecularNeuroscience, 15, Article 984126. https://doi.org/10.3389/fnmol.2022.984126
[67]
Raszewska-Famielec, M. and Flieger, J. (2022) Nanoparticles for Topical Application in the Treatment of Skin Dysfunctions—An Overview of Dermo-Cosmetic and Dermatological Products. InternationalJournalofMolecularSciences, 23, Article 15980. https://doi.org/10.3390/ijms232415980
[68]
Kwatra, S.G., Misery, L., Clibborn, C. and Steinhoff, M. (2022) Molecular and Cellular Mechanisms of Itch and Pain in Atopic Dermatitis and Implications for Novel Therapeutics. Clinical&TranslationalImmunology, 11, e1390. https://doi.org/10.1002/cti2.1390
[69]
Trier, A.M., Mack, M.R., Fredman, A., Tamari, M., Ver Heul, A.M., Zhao, Y., et al. (2022) IL-33 Signaling in Sensory Neurons Promotes Dry Skin Itch. JournalofAllergyandClinicalImmunology, 149, 1473-1480.e6. https://doi.org/10.1016/j.jaci.2021.09.014
[70]
Yamamura, Y., Nakashima, C. and Otsuka, A. (2024) Interplay of Cytokines in the Pathophysiology of Atopic Dermatitis: Insights from Murin Models and Human. FrontiersinMedicine, 11, Article 1342176. https://doi.org/10.3389/fmed.2024.1342176
[71]
Mack, M.R. and Kim, B.S. (2018) The Itch-Scratch Cycle: A Neuroimmune Perspective. TrendsinImmunology, 39, 980-991. https://doi.org/10.1016/j.it.2018.10.001
